vibostolimab

mAbexperimental

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05845814Phase 1/Phase 2 (Phase 2)Jun 23, 2023Merck
NCT05665595Phase 3Jan 25, 2023Merck
NCT05298423Phase 3May 3, 2022Merck
NCT05224141Phase 3Mar 24, 2022Merck
NCT05226598Phase 3Mar 24, 2022Merck
NCT05005442Phase 2Sep 28, 2021Merck
NCT05007106Phase 2Sep 16, 2021Merck
NCT04725188Phase 2Apr 20, 2021Merck
NCT04738487Phase 3Apr 7, 2021Merck
NCT04305054Phase 1/Phase 2 (Phase 2)Jul 3, 2020Merck
NCT04305041Phase 1/Phase 2 (Phase 2)Jul 3, 2020Merck
NCT04303169Phase 1/Phase 2 (Phase 2)Jul 3, 2020Merck
NCT04165070Phase 2Jan 17, 2020Merck
NCT02964013Phase 1Dec 13, 2016Merck
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit141432016
1 organizations
Page 1 / 1